ClinicalTrials.gg
Not yet recruitingNCT07686289Updated Jul 7, 2026

A Controlled Evaluation of Optical Defocus Parameters on Transient Changes in Axial Length Using Kubota Glass

An interventional study of KG1 and KG2 in Myopia, sponsored by Kubota Vision Inc.. Not yet recruiting. Open to participants aged 8 Years to 24 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-07-07.

Sponsored by Kubota Vision Inc. (part of Kubota Pharmaceutical Holdings Co., Ltd.) · Not applicable, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
35
Allocation
Randomized
Ages
8 Years to 24 Years
Sex
All
01

Study summary

This study will assess the optimal performance characteristics of optical defocus on transient changes in axial length with Kubota Glass, using a randomized, double-masked, 5-treatment, 5-period crossover design with contralateral eye control.

02

Conditions studied

  • Myopia

Browse trials for

03

In context

Myopia

1,162 studies on the registry are indexed under Myopia; 228 are open to participants now.

This study's planned enrollment of 35 is below the median of 79 across 926 interventional studies indexed under Myopia.

Browse Myopia studies →

Lead sponsor

Kubota Vision Inc. is the lead sponsor of 21 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
8 Years to 24 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Be of legal age or, if under legal age have written consent of their parent or guardian to participate.
  • Sign written (and the California Bill of Rights, if applicable).
  • Be between age 8-24 (inclusive) and able to understand and assent to participation.
  • Have a spherical component of spectacle prescription between -1.00 and -5.00 diopters (D) (inclusive) in each eye.
  • Have a refractive astigmatism of less than or equal to -1.00 D in each eye.
  • Have axial length between 23.00 and 25.99 millimeters (mm) in each eye.
  • Best Spectacle Corrected Visual Acuity (BSCVA) of 20/25 or better in each eye.
  • Be willing and able to follow instructions and attend the schedule of follow-up visits.

Exclusion criteria

Exclusion Criteria:

  • Unable or unwilling to provide and assent.
  • Eye injury or surgery within twelve weeks immediately prior to enrollment.
  • Currently enrolled in an ophthalmic clinical trial.
  • Pregnant or lactating or expect to become pregnant during the trial (by self-report).
  • Evidence of systemic or ocular abnormality, infection or disease.
  • Use of medications that may affect the eye (including, but not limited to, and antimetabolites).
  • Anisometropia ≥ 2.00.
  • Subjects who have undergone corneal refractive surgery.
  • Use atropine or other anticholinergic drug within the past month.
  • Employees or immediate family members of employees of study sites or sponsor.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
35 participants (estimated)

Study arms

  • Experimental
    Sequence 1

    Device: KG1 · Device: KG2 · Device: KG3 · Device: KG4 · Device: KG5

  • Experimental
    Sequence 2

    Device: KG1 · Device: KG2 · Device: KG3 · Device: KG4 · Device: KG5

  • Experimental
    Sequence 3

    Device: KG1 · Device: KG2 · Device: KG3 · Device: KG4 · Device: KG5

  • Experimental
    Sequence 4

    Device: KG1 · Device: KG2 · Device: KG3 · Device: KG4 · Device: KG5

  • Experimental
    Sequence 5

    Device: KG1 · Device: KG2 · Device: KG3 · Device: KG4 · Device: KG5

  • Experimental
    Sequence 6

    Device: KG1 · Device: KG2 · Device: KG3 · Device: KG4 · Device: KG5

  • Experimental
    Sequence 7

    Device: KG1 · Device: KG2 · Device: KG3 · Device: KG4 · Device: KG5

  • Experimental
    Sequence 8

    Device: KG1 · Device: KG2 · Device: KG3 · Device: KG4 · Device: KG5

  • Experimental
    Sequence 9

    Device: KG1 · Device: KG2 · Device: KG3 · Device: KG4 · Device: KG5

  • Experimental
    Sequence 10

    Device: KG1 · Device: KG2 · Device: KG3 · Device: KG4 · Device: KG5

Interventions

  • DeviceKG1

    Unique Kubota Glass optical defocus parameter

  • DeviceKG2

    Unique Kubota Glass optical defocus parameter

  • DeviceKG3

    Unique Kubota Glass optical defocus parameter

  • DeviceKG4

    Unique Kubota Glass optical defocus parameter

  • DeviceKG5

    Unique Kubota Glass optical defocus parameter

06

What researchers measure

Primary outcomes

  1. Axial length

    Time frame: 1 hour

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jul 2026; primary completion for Dec 2026, 4 months later.

Of 234 industry-sponsored interventional studies with no phase under Myopia, half reached primary completion within 6 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 24. This study's planned 4 months is below that.

Counting every sponsor, half of 434 studies reached it within 14 months; a quarter within 3 and three quarters within 34.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 30, 2026
First posted
Jul 7, 2026
StartEst.
Jul 6, 2026
Primary completionEst.
Dec 1, 2026
CompletionEst.
Dec 31, 2026
Last update
Jul 7, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 7, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07686289
Lead sponsor
Kubota Vision Inc.
Responsible party
Sponsor
First posted
Jul 7, 2026
Start date
Jul 6, 2026 (estimated)
Primary completion
Dec 1, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Jul 7, 2026

Study contacts

Kubota Vision
Contact
boconnor@kubotavision.com
425-527-3260

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion